Answers are grounded in this paper and cite their sources.
This article explores AI-driven approaches that enhance scalability and consistency in biomanufacturing for cell and gene therapy, indicating significant potential for advancement.
Cell and gene therapy (CGT) has demonstrated transformative clinical potential; however, challenges in scalability, cost, and process consistency continue to limit widespread adoption. AI and digital transformation are emerging as critical enablers to address these bottlenecks. From predictive vector design to smart manufacturing and real-time quality control, AI-driven approaches are reshaping the CGT lifecycle. This article explores how integrated digital ecosystems, advanced analytics, and automation accelerate CGT industrialization while highlighting key implementation challenges and regulatory considerations.
No takes yet. Share an insight, caveat, or question.
PK Misra (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: